Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metabolic Imaging of Lower Grade Glioma Using Hyperpolarized 13C Pyruvate
NCT04540107Phase 1Recruiting
- Start
- Jan 2017
- Primary completion
- Jan 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of [1-13C]pyruvate in glioma (2 cohorts). Primary endpoints: Number of treatment-emergent adverse events (AEs) at 4 years, Peak lactate/pyruvate at 4 years and 3 more. Started Jan 2017; status: recruiting.
02
Drugs
[1-13C]pyruvate
03
Conditions
glioma
Beyond the preview
Go deeper on NCT04540107.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04540107.